Insight Molecular Diagnostics Files 8-K
Ticker: IMDX · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1642380
Sentiment: neutral
Topics: financial-reporting, company-update
TL;DR
Insight Molecular Diagnostics (formerly Oncocyte) filed an 8-K on Nov 10, 2025, updating financials.
AI Summary
Insight Molecular Diagnostics Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as Oncocyte Corp, is incorporated in California and headquartered in Nashville, Tennessee.
Why It Matters
This filing provides an update on the company's financial performance and condition, which is crucial for investors to assess its current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate material changes or risks.
Key Players & Entities
- Insight Molecular Diagnostics Inc. (company) — Registrant
- Oncocyte Corp (company) — Former company name
- November 10, 2025 (date) — Date of report
- Nashville, Tennessee (location) — Business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as Financial Statements and Exhibits of Insight Molecular Diagnostics Inc.
When was this report filed?
This report was filed on November 10, 2025.
What were Insight Molecular Diagnostics Inc.'s former names?
Insight Molecular Diagnostics Inc. was formerly known as Oncocyte Corp.
Where is Insight Molecular Diagnostics Inc. headquartered?
Insight Molecular Diagnostics Inc. is headquartered at 2 International Plaza Dr., Suite 510, Nashville, Tennessee 37217.
In which state is Insight Molecular Diagnostics Inc. incorporated?
Insight Molecular Diagnostics Inc. is incorporated in California.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-10 16:11:41
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex99-1.htm (EX-99.1) — 172KB
- ex99-1_001.jpg (GRAPHIC) — 190KB
- ex99-1_002.jpg (GRAPHIC) — 192KB
- ex99-1_003.jpg (GRAPHIC) — 93KB
- ex99-1_004.jpg (GRAPHIC) — 32KB
- ex99-1_05.jpg (GRAPHIC) — 1483KB
- 0001493152-25-021513.txt ( ) — 3132KB
- imdx-20251110.xsd (EX-101.SCH) — 3KB
- imdx-20251110_lab.xml (EX-101.LAB) — 33KB
- imdx-20251110_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSIGHT MOLECULAR DIAGNOSTICS INC. Date: November 10, 2025 By: /s/ Peter Hong Name: Peter Hong Title: Vice President, General Counsel